Jeremy Bartley, MD
Cornea and External Diseases Specialist · Dallas, TXNPI 1467742270
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Rxsight Inc at 59.4% of the total. Reporting peaked in 2024 at $3,569 and has fallen 53.8% since, to $1,647 in 2025.
Across 53 payments — averaging $143.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$5K
- Bausch & Lomb Americas Inc.$1K
- Alcon$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$242
- Johnson & Johnson Surgical Vision, Inc.$191
- Carl Zeiss Meditec USA, Inc.$134
- plus $150 from 2 others
Across 4 payments — averaging $2849.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$6K
- Oyster Point Pharma, Inc.$5K
What the payments were for
- Consulting fees$4,25056%
- Speaking & faculty fees$320%
- Food & beverage$3,33744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 10 | $4,529 |
| Bausch & Lomb Americas Inc. | 11 | $1,232 |
| Alcon | 21 | $1,141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $242 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $191 |
| Carl Zeiss Meditec USA, Inc. | 2 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $110 |
| Biotissue Holdings Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$4,413
- RXSIGHT INJECTOR CARTRIDGE$4,413
- RXSIGHT INJECTOR HANDPIECE$4,413
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,413
- LIGHT ADJUSTABLE LENS (LAL)$4,413
- enVista MX60 IOL$729
- Centurion$477
- CLEARVISC$241
- ACTIVEFOCUS$233
- AcrySof$228
- AcrySof IQ PanOptix$180
- MIEBO$145
- XIIDRA$145
- AMVISC$125
- PanOptix$122
- ENVISTA ENVY IOL$115
- STELLARIS$114
- Tecnis Symfony IOL$105
- Tecnis Symfony Toric IOL$105
- Tecnis Multifocal Family of 1-piece IOLS$105
How this compares
$7,620 in reported general payments places this provider in the 85th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 30 | $25,059 |
| RestasisCyclosporine | 31 | $21,007 |
| Prednisolone Acetate | 373 | $14,038 |
| Loteprednol Etabonate | 59 | $11,514 |
| Cyclosporine | 23 | $10,397 |
| MoxifloxacinMoxifloxacin Hcl | 340 | $7,734 |
| Ketorolac Tromethamine | 273 | $4,745 |
| Brimonidine Tartrate | 20 | $3,253 |
| ValacyclovirValacyclovir Hcl | 32 | $3,213 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 50 | $716 |
| Latanoprost | 83 | $669 |
| Doxycycline Hyclate | 21 | $304 |
| Timolol Maleate | 17 | $241 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 12 | $120 |
| Tobramycin | 16 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $1,232 | $25,05930 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $242 | $11,51459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in Dallas
- Margaret Wang FrenchDallas$5K
- Nhon leDallas$2K
- Justin WilemanDallas$1K
- William WaldropDallas$692
- Robert BowmanDallas$268
- George ThorneDallas$208
- James McCulleyDallas$155
- Steven VerityDallas$40
- Venkateswara MoothaDallas$40
- Forrest SwannWaco$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.